Novartis expats detail their health-tech spinoff DatosX

Desperate to increase cost efficiency after a financially rough 2022, healthcare systems are in varied stages of engagement with the digital health ecosystem. While some are ahead of the curve, many lack the ability to find and assess technologies that promise to tame rising costs and enhance productivity.

Some former members of Novartis’ innovation team are out to change that. They’ve launched a spinoff company that assists provider networks and life science clients in gathering evidence and vetting digital health technology.

The idea for the spinoff, dubbed DatosX, originated within the Swiss drugmakers’ Biome open-innovation hub.